PT  - JOURNAL ARTICLE
AU  - Joshua L. Santarpia
AU  - Danielle N. Rivera
AU  - Vicki L. Herrera
AU  - M. Jane Morwitzer
AU  - Hannah M. Creager
AU  - George W. Santarpia
AU  - Kevin K. Crown
AU  - David M. Brett-Major
AU  - Elizabeth R. Schnaubelt
AU  - M. Jana Broadhurst
AU  - James V. Lawler
AU  - St. Patrick Reid
AU  - John J. Lowe
TI  - Aerosol and Surface Transmission Potential of SARS-CoV-2
AID  - 10.1101/2020.03.23.20039446
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.03.23.20039446
4099  - http://medrxiv.org/content/early/2020/06/03/2020.03.23.20039446.short
4100  - http://medrxiv.org/content/early/2020/06/03/2020.03.23.20039446.full
AB  - The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) originated in Wuhan, China4 in late 2019, and its resulting coronavirus disease, COVID-19, was declared a pandemic by the World Health Organization on March 11, 2020. The rapid global spread of COVID-19 represents perhaps the most significant public health emergency in a century. As the pandemic progressed, a continued paucity of evidence on routes of SARS-CoV-2 transmission has resulted in shifting infection prevention and control guidelines between clasically-defined airborne and droplet precautions. During the initial isolation of 13 individuals with COVID-19 at the University of Nebraska Medical Center, we collected air and surface samples to examine viral shedding from isolated individuals. We detected viral contamination among all samples, indicating that SARS-CoV-2 may spread through both direct (droplet and person-to-person) as well as indirect mechanisms (contaminated objects and airborne transmission). Taken together, these finding support the use of airborne isolation precautions when caring for COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWork was supported by University of Nebraska internal fundingAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is included in manuscript materials